Methylglyoxal bis-guanylhydrazone (MGBG), a potent inhibitor of polyamine synthesis, has demonstrated single agent activity against a number of tumor types including malignant lymphomas and head and neck, esophageal and non-small cell lung cancers. The growth of small cell lung cancer (SCLC) cell lines can be arrested by polyamine inhibition. Therefore a phase II trial was conducted in twenty-four patients with refractory SCLC. MGBG was administered by intravenous infusion at a dose of 500 mg/m 2 per week for four cycles and then every two weeks thereafter. The dose was escalated by 100 mg/m 2 every two weeks in the absence of toxicity _> grade 2. One patient achieved a partial response of objectively measurable lung disease and supraclavicular adenopathy. Three patients had stable disease. Dose limiting toxicity consisted primarily of mild to moderate nausea, vomiting, stomatitis and/or diarrhea. Myelosuppression was uncommon and rarely dose limiting. We conclude that MGBG in the dose and schedule used does not have significant activity as a single agent in previously treated small cell lung cancer.
Introduction
Methylglyoxal bis-guanylhydrazone (MGBG) is a synthetic polycarbonyl compound that has been shown to have useful antitumor activity in patients with advanced malignant lymphomas and head and neck, esophageal and non-small cell lung cancers [1] . Although the exact mechanism of its antitumor activity is not known, MGBG produces a variety of metabolic effects including mitochondrial swelling, uncoupling of oxidative phosphorylation and polyamine depletion [2] . Through potent inhibition of S-adenosylmethionine decarboxylase (SAM-DC), MGBG blocks formation of the amino propyl donor required for the synthesis of spermine and spermidine from putrescine in the polyamine pathway [3] . Inhibition of polyamine biosynthesis is of interest in that high and unperturbed polyamine production appears to be essential to the growth of several human tumors including small cell lung cancer (SCLC) [4] [5] [6] . For these reasons we chose to conduct a phase II trial of MGBG in highly selected patients with refractory SCLC. The following report details the methods and results of the study.
Materials and methods
Twenty-four patients with objectively measurable and histologically confirmed SCLC were entered in the study. Eligibility requirements included Karnofsky performance score _ 50, white blood cell (WBC) count _> 4000/mm 3, platelet count >_ 100,000/mm 3 blood urea nitrogen _< 20 mg%, serum creatinine _< 1.6 mg%, serum bilirubin ___ 2.0 rag%, no treatment for at least the preceding $80 4 weeks and informed consent. At the start of therapy all patients had a complete medical history, physical examination, and laboratory evaluation including complete blood cell (CBC) count with differential and platelet count, fasting blood glucose, urinalysis, 12-channel biochemical screening profile, carcinoembryonic antigen (CEA) and chest roentgenogram. Radionuclide bone and liver scans and chest/abdominal CT scans were obtained as needed. Each patient had a weekly physical examination, toxicity evaluation, CBC, and serum chemistries and a monthly evaluation of chest roentgenogram or diagnostic scan as needed for tumor measurements.
MGBG was administered by injection through an established free-flowing iv line over 30 minutes. The initial dose of 500 mg/m' was administered weekly for four cycles and then on alternate weeks. Criteria used for dose adjustments followed the standard toxicity criteria. The dose was escalated by 100 mg/m 2 in the absence of toxicity _> grade 2. The dose was attenuated by 25~ in the presence of grade 3 toxicity and 50~ in the presence of grade 4 toxicity. An adequate trial required a minimum of three cycles of MGBG.
Therapeutic response criteria were defined as: partial response (PR) -__ 50~ decrease of all measurable lesions for at least 4 weeks: Disease progression (PD) -a _> 25~ increase in the sum of the products of measureable lesions or the appearance of new lesions; and stable disease (STAB) -disease regression less than that needed for PR or disease progression less than that needed for PD for at least two months.
Patient characteristics
There were 15 males and 9 females with a median age of 59 years (range, 47-71) and a median Karnofsky performance status of 70 (range, 50-90). All patients had received prior combination chemotherapy including cyclophosphamide (100o70), doxorubicin (96%), vincristine (96~ VP-16-213 (46%), cisplatin (46o70), methotrexate (22o70), CCNU (22%), or other (25O7o). Sixteen patients (67o7o) had received only one prior combination chemotherapy treatment regimen. Ten patients (42~ had received radiation therapy to whole brain and eight patients (33%) had received it to the mediastinum. Sixteen patients (67%) had more than one site of tumor involvement at entry into this study including lung (2), lymph nodes (6), liver (7), spleen (1), adrenal (2), bone (2), and subcutaneous tissue (1).
Results
Twenty-two of 24 patients entered into the study are considered evaluable for response and toxicity. The two unevaluable cases include one patient who had an unrelated death 5 days after the first dose of MGBG and another who was lost to follow up after 2 doses. There was only one objective response (PR) in 22 evaluable patients (observed response rate = 4.5~ 95~ confidence interval = 0.2-19.8~
The response occurred after 2 doses of MGBG in objectively measurable lung disease and supraclavicular adenopathy in a patient whose disease had progressed after a partial response to CAV chemotherapy. The patient died after 6 cycles (2 months) of MGBG due to progressive brain metastases but remained in PR extracranially. Three additional patients had stable disease.
The most common and dose limiting toxicities occurred in the gastrointestinal tract. Mild to moderate (grade 1-2) diarrhea and/or stomatitis occurred in 10 patients (45%), nausea and vomiting occurred in 10 patients (45~ and anorexia occurred in 7 patients (32~ Grade 1-3 myalgias and/or fatigue occurred in 8 patients (36%). Leukopenia and thrombocytopenia were uncommon and rarely dose limiting. Only two patients developed grade 1 leukopenia, and thrombocytopenia occurred in 5 patients (3 = grade 1, 1 = grade 2, and 1 = grade 4). One patient complained of moderate to severe jaw pain for 1-2 days after each dose of MGBG and one patient developed grade 1 dermatitis.
The median number of doses of MGBG given was 4 per patient (range, [1] [2] [3] [4] [5] [6] [7] [8] . Two patients required dose attenuations due to myalgias, thrombocytopenia or gastrointestinal toxicity and three 
Discussion References
The resurgence of interest in MGBG in the late 1970's was due to the development of a more tolerable weekly schedule of administration [1, 7] and the discovery of its potency as an polyamine inhibitor [3] . The products of polyamine synthesis, putrescine, spermidine and spermine have been implicated in the maintenance of cell growth and it was hypothesized that the inhibition of this pathway could provide an effective tool for arresting the growth of cancer cells [4, 51. Alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase which catalyzes the rate limiting step in polyamine synthesis, has been of particular interest. Luk et al. [6] have shown that the growth and viability of human SCLC cells in culture is markedly inhibited by DFMO. However, only one partial response has been observed in 33 SCLC patients treated with DFMO in phase I and II trials [8-101. In this study, MGBG demonstrated little activity (one PR) in 24 good performance status patients with SCLC, 16 of whom had received only one prior treatment regimen. Although its pattern of toxicity, including lack of significant myelosuppression, make MGBG an attractive agent to incorporate into combination regimens used in SCLC, this study as well as the negative one reported by Scher et al. which used a dose and schedule similar to ours [11] fail to justify further studies of this compound.
